Major hurdles to the use of tyrosine kinase inhibitors in clinical prevention/interception studies: Do preclinical studies with EGFR inhibitors suggest approaches to overcome some of the limitations.

Dragnev, Konstantin H; Dragnev, Christo P C; Lubet, Ronald A

Dragnev, Konstantin H; Dragnev, Christo P C; Lubet, Ronald A.

Afiliação

Dragnev KH; Dartmouth Cancer Center, Lebanon, NH, United States.
Dragnev CPC; Colby College, Waterville, ME, United States.
Lubet RA; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, United States.

Front Cell Dev Biol ; 11: 1170444, 2023.

Article em En | MEDLINE | ID: mdl-37169023

Palavras-chave

EGFR inhibitiors; HER-2 inhibitors; cancer interception; cancer prevention trials; clinical cancer prevention; tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Screening_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google